Sun Pharmaceutical Industries Ltd. closed 10.67% short of its 52-week high of 1,960.20 rupees, which the company achieved on September 30th.

After a legal decision delayed its entry last fall, Sun Pharma has received the all-clear to tap into the U.S. | After Sun ...

Sun Pharma declined 0.93 per cent to Rs 1,689.35. About10 per cent of the Sun Pharma's US specialty revenues is formulated in ...

The pharma sector is likely to maintain steady earnings. Most brokerages flag US business recovery as the key swing factor ...

A Federal Circuit panel looked likely to reverse a district court’s order blocking Sun Pharmaceutical Industries Ltd. from ...

The rise in the Sun Pharma share price came after a favourable ruling from a US court regarding its planned launch of ...

Emkay Global maintains a 'Buy' rating on Sun Pharma after the US Court of Appeals vacates the injunction against Leqselvi's ...

Art Garfunkel is breaking the sound of silence around his experience with plaque psoriasis. | Art Garfunkel is breaking the ...

Sun Pharmaceutical Industries Ltd. closed 13.65% short of its 52-week high of 1,960.20 rupees, which the company reached on September 30th.

Indian pharma players have been witnessing reprieve from price erosion and US product launches in the past few quarters. A ...

Sun Pharmaceuticals is one of India’s largest pharmaceutical companies with over 8% share in the domestic market. It owns 35 ...

Indian equities soar to record highs, erasing year-to-date losses in best week in four years, led by financial sector.